Table 4.
Variables associated with therapeutic response to statin therapy in 40 PAP patients.
| Feature | Responders (n = 26) | Nonresponders (n = 14) | p value |
|---|---|---|---|
| Age (year) | 49.58 ± 11.19 | 44.21 ± 14.85 | 0.206 |
| Gender (female) | 9 (34.62) | 9 (64.29) | 0.072 |
| Smoking history (Y) | 14 (53.85) | 0 (0.00) | 0.002 |
| GM-CSF antibody (μ g/mL) | 33.34 ± 31.86 | 15.75 ± 10.48 | 0.015 |
| TC (mmol/L) | 4.19 ± 0.81 | 4.21 ± 0.98 | 0.952 |
| HDL (mmol/L) | 1.07 ± 0.43 | 1.28 ± 0.40 | 0.138 |
| LDL (mmol/L) | 2.53 ± 0.74 | 2.44 ± 0.78 | 0.707 |
| TC/HDL | 4.39 ± 1.41 | 3.47 ± 1.00 | 0.035 |
| PaO2 (mmHg) | 68.33 ± 11.02 | 71.14 ± 12.53 | 0.467 |
| Alveolar arterial oxygen gradient (A-aDO2) (mmHg) | 35.91 ± 14.23 | 31.28 ± 11.88 | 0.307 |
| Disease severity score | 2.69 ± 0.97 | 2.50 ± 1.09 | 0.570 |
| LDH (U/L) | 281.62 ± 97.28 | 243.36 ± 73.16 | 0.206 |
| CEA (ng/mL) | 3.95 ± 4.52 | 3.82 ± 4.12 | 0.931 |
| CYF21-1 (ng/mL) | 9.89 ± 8.78 | 8.22 ± 6.76 | 0.539 |
| DLCO%pred | 60.04 ± 22.99 | 60.67 ± 17.15 | 0.929 |
| Total opacification percentage of whole lung (%) | 35.45 ± 23.68 | 26.99 ± 24.92 | 0.296 |
| Percentage of HU value of [-300, 49)H (%) | 8.26 ± 7.55 | 5.21 ± 6.26 | 0.205 |
| Percentage of HU value of [50+)H (%) | 2.40 ± 2.82 | 0.83 ± 1.20 | 0.018 |
GM-CSF antibody: granulocyte-macrophage colony-stimulating factor antibody; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; LDH: lactate dehydrogenase; CEA: carcinoembryonic antigen; CYFRA21-1: cytokeratin 21-1; PaO2: partial pressure of arterial oxygen; DLCO: carbon monoxide diffusion capacity; HU: Hounsfield unit.